Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06974773 · ClinicalTrials.gov registry record · NA

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

A NA study of Endometriosis, sponsored by Samphire Group.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06974773: Recruiting NA study of Endometriosis, sponsored by Samphire Group.

NCT06974773 is a NA study of Endometriosis that is actively recruiting participants, run by Samphire Group. The registered enrollment target is 120 participants, below the 262-participant average among 48 other Endometriosis trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06974773, a NA study of Endometriosis, is actively recruiting participants, sponsored by Samphire Group.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Be followed for 90 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.

Primary Outcome

Average change from baseline in daily self-reported pain intensity related to endometriosis, using a 0-10 Numerical Rating Scale (NRS). This will be measured separately for dysmenorrhea (Dysmenorrhea NRS; DYS NRS) and non-menstrual pelvic pain (Non-Menstrual Pelvic Pain; NMPP NRS). Collected via mobile app. A decrease in NRS, NMPP NRS and DYS NRS scores indicate a better outcome, as it reflects reduced pain intensity.

Conditions Studied

Interventions

  • DEVICE NettleEndo
  • DEVICE Sham NettleEndo Device

Study Locations (1)

California

  • Alethios, Inc. - San Francisco

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-12-04
Est. Completion 2026-08-01
Phase NA
Samphire Group

2 total trials

What NCT06974773 shows while recruiting

NCT06974773 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 262-participant average among 48 other Endometriosis trials with a reported enrollment target (54% lower).

The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which NettleEndo is the first listed.

NCT06974773 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06974773 about?

NCT06974773 is a clinical study titled "Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups". The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main...

What is the current status of trial NCT06974773?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-12-04. Estimated completion is 2026-08-01.

What conditions does trial NCT06974773 study?

This clinical trial studies the following conditions: Endometriosis.

What interventions are being tested in trial NCT06974773?

The interventions under investigation include: NettleEndo (DEVICE), Sham NettleEndo Device (DEVICE).

Who is sponsoring clinical trial NCT06974773?

This trial is sponsored by Samphire Group, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06974773 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometriosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06974773's enrollment target sits among peer trials

120 18th of 48 higher than 27 of 48 other Endometriosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06974773, the US trial registry maintained by the National Library of Medicine. NCT06974773 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.